Eledon Pharmaceuticals
ELDN
83 hedge funds and large institutions have $130M invested in Eledon Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
11% more funds holding
Funds holding: 75 → 83 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 64.43% → 64.21% (-0.22%)
18% less capital invested
Capital invested by funds: $159M → $130M (-$28.3M)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
87% less call options, than puts
Call options by funds: $36K | Put options by funds: $282K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.42M |
| 2 |
Millennium Management
New York
|
+$2.85M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$2.84M |
| 4 |
2L
22NW LP
Seattle,
Washington
|
+$2.62M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$776K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$4.85M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.51M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.22M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.01M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$971K |
ELDN Hedge Fund Activity: Q1 2025 in Review
83 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2025, worth a combined $130M — down 18% from $159M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ELDN positions and 10 closed out — a net gain of 8 holders — while 17 added to existing stakes and 21 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $5.42M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $4.85M sold.
- 83 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2025, up from 75 in Q4 2024.
- Funds reported $130M of Eledon Pharmaceuticals stock for Q1 2025, down 18% quarter-over-quarter.
- 18 funds opened new Eledon Pharmaceuticals positions in Q1 2025 and 10 closed out, a net change of +8 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2025 was Susquehanna International Group, an estimated $5.42M added.
- The largest Eledon Pharmaceuticals seller in Q1 2025 was Frazier Life Sciences Management, an estimated $4.85M sold.
Based on aggregated 13F filings for Q1 2025.